GreenLight Biosciences is a biotechnology company that specializes in RNA-based solutions for agricultural and pharmaceutical applications. Founded in 2008 and headquartered in Medford, Massachusetts, with an additional location in North Carolina, the company utilizes its Unconstrained Metabolism technology platform to convert renewable substrates into valuable chemicals and fuels. This platform allows for significant flexibility and control in the production process. GreenLight is also focused on developing RNA products aimed at improving crop management, plant protection, and animal health, while advancing vaccine development and pandemic preparedness. In addition to these applications, the company is working on mRNA-based vaccine candidates targeting seasonal and pandemic influenza, as well as other emerging viruses, to enhance public health. Through its innovations, GreenLight aims to provide sustainable solutions that contribute to global food security and health.
OncoMyx Therapeutics, Inc. is a biotechnology company specializing in the development of oncolytic immunotherapies utilizing the myxoma virus (MYXV) to stimulate immune responses against cancer. Founded in 2018 and based in Phoenix, Arizona, the company focuses on targeting both hematologic and solid tumors through its innovative MYXV platform. This platform employs a novel systemic delivery method that allows the myxoma virus to be carried by human leukocytes, enabling it to effectively infect tumor cells. By assembling a highly skilled team in oncolytic virus research, OncoMyx aims to advance a pipeline of therapeutic options designed to improve outcomes for cancer patients.
OncoMyx Therapeutics, Inc. is a biotechnology company specializing in the development of oncolytic immunotherapies utilizing the myxoma virus (MYXV) to stimulate immune responses against cancer. Founded in 2018 and based in Phoenix, Arizona, the company focuses on targeting both hematologic and solid tumors through its innovative MYXV platform. This platform employs a novel systemic delivery method that allows the myxoma virus to be carried by human leukocytes, enabling it to effectively infect tumor cells. By assembling a highly skilled team in oncolytic virus research, OncoMyx aims to advance a pipeline of therapeutic options designed to improve outcomes for cancer patients.
Imago BioSciences is a clinical-stage biotechnology company based in San Carlos, California, focused on developing innovative therapies for hematologic diseases, including leukemia and myelodysplastic syndromes. Established in 2012, the company specializes in small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme crucial for blood cell production in the bone marrow. Its lead candidate, Bomedemstat, is an orally available inhibitor of LSD1, being evaluated for its potential to modify the disease course in patients with myeloproliferative neoplasms, a group of chronic bone marrow cancers. Imago aims to translate advanced scientific insights into effective treatments that can significantly improve the quality and duration of life for patients facing these challenging conditions.
InterVenn Biosciences Inc. is a biotechnology company that specializes in artificial intelligence-based mass spectrometry technology for glycoproteomics. Founded in 2017 and headquartered in South San Francisco, California, with additional offices in the Philippines, Malaysia, and Australia, InterVenn focuses on the identification, quantification, and classification of glycoproteomic signals in human blood and tissue. Its VISTA platform is the first commercially available system that assesses protein glycosylation in a site-specific manner, enabling the discovery of biomarkers for various conditions, including cancers, autoimmunity, fibrosis, and neurodegeneration. The company's technology aims to facilitate early cancer detection and improve patient care through actionable insights derived from glycoproteomic analysis.
Congenica Ltd. is a UK-based company that specializes in clinical data solutions for genetic diagnosis. Founded in 2012, it leverages pioneering research from the Wellcome Trust Sanger Institute and NHS clinicians to develop its flagship product, the Sapientia platform. This clinical genomic analytics tool integrates human DNA sequences with deep clinical phenotyping, allowing clinicians and researchers to interpret genetic diseases effectively. Sapientia supports clinical diagnosis, prognosis, and research, and plays a crucial role in personalized medicine applications, including the creation of disease registries and the identification of patient populations for clinical studies. By providing diagnostic decision support and associated services, Congenica aims to enhance patient care through precise diagnoses and the curation of evolving knowledge bases, ultimately contributing to advancements in clinical trials and drug development.
Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration.
The company was formerly known as Genomic Profiling Systems and changed its name to Rapid Micro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.
GreenLight Biosciences is a biotechnology company that specializes in RNA-based solutions for agricultural and pharmaceutical applications. Founded in 2008 and headquartered in Medford, Massachusetts, with an additional location in North Carolina, the company utilizes its Unconstrained Metabolism technology platform to convert renewable substrates into valuable chemicals and fuels. This platform allows for significant flexibility and control in the production process. GreenLight is also focused on developing RNA products aimed at improving crop management, plant protection, and animal health, while advancing vaccine development and pandemic preparedness. In addition to these applications, the company is working on mRNA-based vaccine candidates targeting seasonal and pandemic influenza, as well as other emerging viruses, to enhance public health. Through its innovations, GreenLight aims to provide sustainable solutions that contribute to global food security and health.
Aria CV was founded in 2010 by Drs. John Scandurra and Karl Vollmers, formerly Fellows at the University of Minnesota’s Medical Devices Center. Aria has an exclusive license to certain patents from the University of Minnesota. Aria CV’s device has the potential to improve outcomes by reducing the workload on the right side of the heart.
P2 Science, Inc. is a bio-renewable chemistry company based in Woodbridge, Connecticut, specializing in the development and production of specialty chemicals derived from renewable feedstocks, such as vegetable oils. Founded in 2009 by a team that includes Yale scientists and an experienced chemical industry executive, the company focuses on creating high-value ingredients for flavors, fragrances, cosmetics, and other applications. P2 Science aims to provide sustainable alternatives to traditional petrochemical products, catering to diverse markets, including personal care, household cleaning, agriculture, and environmental remediation. Their innovative technology enables the conversion of renewable resources into cost-effective chemical solutions, addressing the increasing demand for greener options among major users in the specialty chemicals sector. The company also maintains a laboratory in New Haven, Connecticut, to support ongoing research and partnerships throughout the supply chain.
Acutus Medical, Inc. is an arrhythmia management company that specializes in developing medical technologies for diagnosing and treating complex cardiac arrhythmias. Founded in 2011 and based in Carlsbad, California, the company designs, manufactures, and markets a comprehensive range of tools for catheter-based ablation procedures. Its product offerings include advanced imaging and mapping systems, such as the AcQMap console and workstation, along with diagnostic catheters and therapeutic devices like ablation catheters and robotic navigation systems. Acutus Medical's innovative platform enables electrophysiologists to visualize the heart's activation patterns, facilitating more effective treatment of arrhythmias. The company collaborates with medical scientists and engineers in the U.S. and Europe to enhance its product development and provides solutions to hospitals and electrophysiologists globally.
OncoMyx Therapeutics, Inc. is a biotechnology company specializing in the development of oncolytic immunotherapies utilizing the myxoma virus (MYXV) to stimulate immune responses against cancer. Founded in 2018 and based in Phoenix, Arizona, the company focuses on targeting both hematologic and solid tumors through its innovative MYXV platform. This platform employs a novel systemic delivery method that allows the myxoma virus to be carried by human leukocytes, enabling it to effectively infect tumor cells. By assembling a highly skilled team in oncolytic virus research, OncoMyx aims to advance a pipeline of therapeutic options designed to improve outcomes for cancer patients.
Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration.
The company was formerly known as Genomic Profiling Systems and changed its name to Rapid Micro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.
Liquidia Technologies is a late-stage clinical biopharmaceutical company based in Morrisville, North Carolina, that specializes in the development and commercialization of human therapeutics. The company utilizes its proprietary PRINT technology, a particle engineering platform that allows for the precise production of uniform drug particles, aimed at improving the safety, efficacy, and performance of various therapies. Liquidia is currently advancing two key product candidates: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for addressing local post-operative pain. In addition to its internal pipeline, Liquidia collaborates with leading pharmaceutical companies to leverage its PRINT technology across multiple therapeutic areas and drug types. The company also offers strategy and commercialization services for rare disease pharmaceutical products, including a generic formulation of treprostinil for pulmonary arterial hypertension. Founded in 2004, Liquidia Technologies continues to focus on transforming patient care through innovative therapeutic solutions.
P2 Science, Inc. is a bio-renewable chemistry company based in Woodbridge, Connecticut, specializing in the development and production of specialty chemicals derived from renewable feedstocks, such as vegetable oils. Founded in 2009 by a team that includes Yale scientists and an experienced chemical industry executive, the company focuses on creating high-value ingredients for flavors, fragrances, cosmetics, and other applications. P2 Science aims to provide sustainable alternatives to traditional petrochemical products, catering to diverse markets, including personal care, household cleaning, agriculture, and environmental remediation. Their innovative technology enables the conversion of renewable resources into cost-effective chemical solutions, addressing the increasing demand for greener options among major users in the specialty chemicals sector. The company also maintains a laboratory in New Haven, Connecticut, to support ongoing research and partnerships throughout the supply chain.
Chrono Therapeutics Inc., a digital transdermal drug delivery company, develops SmartStop, a digital nicotine replacement therapy. Its wearable solution tailors the timing and dose sizes of drugs, preempts predictable peak disease, and addiction symptoms with a device. The company was incorporated in 2003 and is based in Hayward, California.
ViewRay, Inc. specializes in the design, manufacture, and marketing of advanced radiation therapy systems, particularly the MRIdian system, which is the first MRI-guided radiation therapy technology that allows simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology with radiation delivery and proprietary software, enabling clinicians to accurately locate, target, and track soft-tissue tumors during treatment. By providing real-time imaging, MRIdian enhances visibility of tumors, thus allowing for precise radiation delivery while minimizing exposure to surrounding healthy tissue. This capability addresses significant limitations of traditional external-beam radiation therapies and expands treatment options for patients who may not have been eligible for radiation therapy previously. ViewRay serves a diverse client base, including university hospitals, community hospitals, and freestanding cancer centers, through a direct sales force and distribution network. The company, founded in 2004 and headquartered in Oakwood, Ohio, has operations in the United States and several European countries.
Iconic Therapeutics, Inc. operates as a biopharmaceutical company that translates tissue factor biology in angiogenesis, inflammation, and metastasis to develop new therapeutics for retinal disease and cancer. Its products include ICON-1, a fusion protein designed to address the basis of vision loss in age-related macular degeneration. Iconic Therapeutics, Inc. was incorporated in 2002 and is based in South San Francisco, California.
Acutus Medical, Inc. is an arrhythmia management company that specializes in developing medical technologies for diagnosing and treating complex cardiac arrhythmias. Founded in 2011 and based in Carlsbad, California, the company designs, manufactures, and markets a comprehensive range of tools for catheter-based ablation procedures. Its product offerings include advanced imaging and mapping systems, such as the AcQMap console and workstation, along with diagnostic catheters and therapeutic devices like ablation catheters and robotic navigation systems. Acutus Medical's innovative platform enables electrophysiologists to visualize the heart's activation patterns, facilitating more effective treatment of arrhythmias. The company collaborates with medical scientists and engineers in the U.S. and Europe to enhance its product development and provides solutions to hospitals and electrophysiologists globally.
Vittamed Ltd. focuses on developing non-invasive medical devices for measuring intracranial pressure and monitoring cerebrovascular autoregulation, targeting patients with neurological diseases, post-stroke complications, and traumatic brain injuries. Established in 2013, the company is headquartered in Carlisle, Massachusetts, with additional offices in Boston and research and development operations in Lithuania. Vittamed's suite of ultrasound-based devices allows for the real-time assessment of intracranial pressure and cerebral blood flow autoregulation, with its diagnostic methods having undergone clinical testing in prominent neurodiagnostic centers across Europe and the United States.
ViewRay, Inc. specializes in the design, manufacture, and marketing of advanced radiation therapy systems, particularly the MRIdian system, which is the first MRI-guided radiation therapy technology that allows simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology with radiation delivery and proprietary software, enabling clinicians to accurately locate, target, and track soft-tissue tumors during treatment. By providing real-time imaging, MRIdian enhances visibility of tumors, thus allowing for precise radiation delivery while minimizing exposure to surrounding healthy tissue. This capability addresses significant limitations of traditional external-beam radiation therapies and expands treatment options for patients who may not have been eligible for radiation therapy previously. ViewRay serves a diverse client base, including university hospitals, community hospitals, and freestanding cancer centers, through a direct sales force and distribution network. The company, founded in 2004 and headquartered in Oakwood, Ohio, has operations in the United States and several European countries.
PrIME Biologics Pte Ltd. develops and manufactures therapeutic plasma products. It develops therapeutic Albumin, IVIG, FVIII, and FIX from human plasma; other therapeutic plasma based products; and hyperimmune therapies and specialty plasma therapeutics. PrIME Biologics Pte Ltd. was formerly known as Singapharm Pte Ltd. and changed its name to PrIME Biologics Pte Ltd. in August 2011. The company was incorporated in 2010 and is based in Singapore. PrIME Biologics Pte Ltd. is a former subsidiary of NuSep Holdings Ltd.
Invendo Medical GmbH specializes in the development, manufacturing, and distribution of sterile, single-use, and lightweight robotically-assisted endoscopy products aimed at gastroenterology and gastrointestinal surgery. The company's flagship product, the invendoscopy E200 System, comprises a sterile colonoscope, a handheld control body, and a supply and processing unit, designed to enhance the endoscopic experience for both patients and healthcare providers. Founded in 2001 and based in Weinheim, Germany, Invendo Medical strives to be a leader in the disposable endoscopy market by focusing on innovation that improves patient compliance and increases the number of procedures performed. The company serves healthcare facilities primarily in the United States and Europe and operates as a subsidiary of Ambu A/S since 2017.
Gevo, Inc. operates as a renewable fuels company. It commercializes gasoline, jet fuel, and diesel fuel to achieve zero carbon emissions, and reduce greenhouse gas emissions with sustainable alternatives. The company uses low-carbon renewable-resource-based carbohydrates as raw materials and is developing renewable electricity and renewable natural gas for use in production processes. It products also include renewable biodiesel, isooctane, isobutanol, sustainable aviation fuel, isobutylene, ethanol, and animal feed. The company was formerly known as Methanotech, Inc. and changed its name to Gevo, Inc. in March 2006. Gevo, Inc. was founded in 2005 and is headquartered in Englewood, Colorado.